These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 9664152)
21. Proliferative activity and loss of function of tumour suppressor genes as 'biomarkers' in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma. Girod SC; Pfeiffer P; Ries J; Pape HD Br J Oral Maxillofac Surg; 1998 Aug; 36(4):252-60. PubMed ID: 9762452 [TBL] [Abstract][Full Text] [Related]
22. [Expression of bcl-2, Ki-67 and p-53 in uveal melanomas]. Krvavica A; Talan-Hranilović J; Belicza M Acta Med Croatica; 2008 Jul; 62(3):267-71. PubMed ID: 18843846 [TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. Sparrow LE; English DR; Taran JM; Heenan PJ Am J Dermatopathol; 1998 Feb; 20(1):12-6. PubMed ID: 9504663 [TBL] [Abstract][Full Text] [Related]
24. The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx. Pignataro L; Capaccio P; Pruneri G; Carboni N; Buffa R; Neri A; Ottaviani A J Laryngol Otol; 1998 May; 112(5):455-9. PubMed ID: 9747474 [TBL] [Abstract][Full Text] [Related]
25. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Chana JS; Wilson GD; Cree IA; Alexander RA; Myatt N; Neale M; Foss AJ; Hungerford JL Br J Ophthalmol; 1999 Jan; 83(1):110-4. PubMed ID: 10209447 [TBL] [Abstract][Full Text] [Related]
26. [Survival of patients with laryngeal cancer and some prognostic factors]. Gryczyński M; Kobos J; Murlewska A; Pietruszewska W Otolaryngol Pol; 2003; 57(3):329-40. PubMed ID: 14524174 [TBL] [Abstract][Full Text] [Related]
27. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Moch H; Sauter G; Gasser TC; Buchholz N; Bubendorf L; Richter J; Jiang F; Dellas A; Mihatsch MJ Urol Res; 1997; 25 Suppl 1():S25-30. PubMed ID: 9079753 [TBL] [Abstract][Full Text] [Related]
28. Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma. Mäkinen K; Hakala T; Lipponen P; Alhava E; Eskelinen M Anticancer Res; 1998; 18(1B):615-8. PubMed ID: 9568186 [TBL] [Abstract][Full Text] [Related]
29. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions. Chorny JA; Barr RJ; Kyshtoobayeva A; Jakowatz J; Reed RJ Mod Pathol; 2003 Jun; 16(6):525-9. PubMed ID: 12808056 [TBL] [Abstract][Full Text] [Related]
30. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343 [TBL] [Abstract][Full Text] [Related]
31. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pinto AE; André S; Laranjeira C; Soares J Pathology; 2005 Feb; 37(1):45-50. PubMed ID: 15875733 [TBL] [Abstract][Full Text] [Related]
32. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Dellas A; Schultheiss E; Almendral AC; Gudat F; Oberholzer M; Feichter G; Moch H; Torhorst J Int J Cancer; 1997 Aug; 74(4):421-5. PubMed ID: 9291432 [TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of Ki-67, p53, and Bcl-2 expression in prostate cancer patients with lymph node metastases: a retrospective immunohistochemical analysis. Masuda M; Takano Y; Iki M; Asakura T; Hashiba T; Noguchi S; Hosaka M Pathol Int; 1998 Jan; 48(1):41-6. PubMed ID: 9589463 [TBL] [Abstract][Full Text] [Related]
34. Chromosomal abnormalities, p53 and Bcl-2 expression and clinical outcome in choroidal melanoma. Erol N; Oner U; Artan S; Işiksoy S; Yurdakul S Melanoma Res; 2004 Dec; 14(6):473-8. PubMed ID: 15577317 [TBL] [Abstract][Full Text] [Related]
35. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045 [TBL] [Abstract][Full Text] [Related]
36. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687 [TBL] [Abstract][Full Text] [Related]
37. Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications. Antonescu CR; Leung DH; Dudas M; Ladanyi M; Brennan M; Woodruff JM; Cordon-Cardo C Am J Pathol; 2000 Mar; 156(3):977-83. PubMed ID: 10702413 [TBL] [Abstract][Full Text] [Related]
38. [Gastric cancer and tumor growth regulation. Study of cell proliferation markers and protein complex p53/p21WAF1/CIP1/mdm-2]. Villaseca M; Araya JC; Roa I; Roa JC Rev Med Chil; 2000 Feb; 128(2):127-36. PubMed ID: 10962880 [TBL] [Abstract][Full Text] [Related]
39. Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67. Engellau J; Persson A; Bendahl PO; Akerman M; Domanski HA; Bjerkehagen B; Lilleng P; Weide J; Rydholm A; Alvegård TA; Nilbert M Virchows Arch; 2004 Sep; 445(3):224-30. PubMed ID: 15309631 [TBL] [Abstract][Full Text] [Related]
40. Prediction of aggressiveness of gastrointestinal stromal tumours based on immunostaining with bcl-2, Ki-67 and p53. Meara RS; Cangiarella J; Simsir A; Horton D; Eltoum I; Chhieng DC Cytopathology; 2007 Oct; 18(5):283-9. PubMed ID: 17883690 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]